Details der Publikation - Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients with functional kidney transplantation.

Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients with functional kidney transplantation. : Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients with functional kidney transplantation.

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	WHO International Clinical Trials Registry Platform - (2021) vom: 29. Nov. Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients with functional kidney transplantation.;Therapeutic area: Body processes [G] - Immune system processes [G12] Phase: Phase 4 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 16-04-2021, Last updated: 2022-11-24

ICTRP ID:	EUCTR2021-002014-14-CZ COV-PBO-MO28

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG007626991

Internformat


LEADER	01000caa a22002652 4500
001	CTG007626991
003	DE-627
005	20230425182047.0
007	cr uuu---uuuuu
008	210525s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG007626991
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2021-002014-14-CZ
035			\|a (UBBS_Klinische_Studien_WHO)COV-PBO-MO28
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients with functional kidney transplantation. \|b Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients with functional kidney transplantation.
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 16-04-2021, Last updated: 2022-11-24
650		4	\|a Medical Condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients with functional kidney transplantation.;Therapeutic area: Body processes [G] - Immune system processes [G12]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 4
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2021) vom: 29. Nov.
773	1	8	\|g year:2021 \|g day:29 \|g month:11
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002014-14 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 29 \|c 11

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände